Altasciences to present Continuing Education Course at the New York State Bar Association
LAVAL, QC, Canada (September 25, 2018) — Altasciences is pleased to announce that Dr. Graham K. Wood, Chief R&D Officer at Altasciences, is presenting at a Continuing Legal Education program entitled Practical Implications of Decriminalized Marijuana for the Legal Practitioner on Wednesday, October 3. The program, which offers 7.0 MCLE credits, is open to members of the New York State Bar Association, who will hear Dr. Wood share his knowledge in the cannabis field, specifically as it relates to Clinical Research.
Dr. Wood has a Ph.D. in Neurology and Neurosurgery from McGill University, has worked as a Research Fellow at the National Institute of Mental Health, and has almost 20 years of experience in designing and conducting clinical pharmacology studies. His deep and broad understanding of the cognitive effects of cannabis is the basis for his testimony to the Canadian Senate on the effects of Cannabis on driving, and he has designed a number of recent first-in-human studies on the safety, tolerability, and cognitive effects of cannabis.
“As the legal landscape around marijuana continues to evolve, reliable clinical research on the effects of cannabis in humans becomes increasingly important, whether the use will be for medical or recreational purposes. It was an educational experience to be part of recent studies in the area, and I look forward to sharing the insights with the New York State Bar”, said Dr. Wood.
The CLE program is organized by the Committee on Continuing Legal Education of the New York State Bar Association, and is sponsored by Barclay Damon LLP. It is also co-sponsored by the Committee on Cannabis Law, the Committee on Continuing Legal Education and the General Practice Section of the New York State Bar Association.
Altasciences is a mid-size CRO focused on early phase drug development, involved in the study of cannabis for over 10 years, with 34 studies completed to date; 14 focused on pharmacokinetics, 1 first-in-human, and one focused on human abuse liability, as well as 18 others.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
For more information
Julie-Ann Cabana
jcabana@altasciences.com
913 304-4505
Pain – is it all in your head?
Pain is a fascinating phenomenon, acting as a physiological warning system that alerts us of potential dangers in our environment.
Dr. William J. Foster Joins Altasciences as Principal Investigator
LAVAL, QC, Canada (September 6, 2018) — Altasciences is pleased to welcome Dr. William J. Foster, MD, PhD, FRCSC, to the Altasciences family as Principal Investigator and Consultant on clinical trials. Dr. Foster, originally from the U.S.A., is a practicing retinal physician in Montreal, Canada, a Professor of Bioengineering, and a Member of the Institute for Regenerative Medicine and Engineering at Temple University in Philadelphia.
“Dr. Foster’s unique background in medicine, bioengineering and biophysics, along with his broad range of expertise in preclinical and clinical research, are an ideal complement to Altasciences as we grow and further develop new areas of specialization. His insight was instrumental in designing one of our upcoming first-in-human studies on an ocular product,” said Ingrid Holmes, General Manager, Montreal Clinical Operations, at Altasciences.
Holding an MD from Duke and PhD from Harvard University, Dr. Foster is a Diplomate of the American Board of Ophthalmology, a Diplomate of the American Board of Preventive Medicine in Clinical Informatics, a Fellow of the American Academy of Ophthalmology, and a Fellow of the Royal College of Surgeons of Canada. In addition to his clinical work, Dr. Foster does translational research to improve outcomes for patients with different retinal diseases, ranging from the application of high-tech polymeric compounds to the repair of retinal detachments and delivery of nanoparticle therapeutics to computational modeling of fluid flow in the eye during different diseases and treatments. He is the current Chair of the CME Committee of the Association for Research in Vision & Ophthalmology, and is a Grant Reviewer for the National Institutes of Health (NIH) Sensory Technologies Study Section.
“I’ve always been passionate about translational and early-stage clinical research. I look forward to working closely with the well-versed team of experts at Altasciences to help our clients in their efforts to enhance vision research that will ultimately lead to new therapies and methods for disease detection,” mentioned Dr. Foster.
Dr. Foster’s peer-reviewed publications are numerous and he has spoken at many national and international scientific conferences. He is on the editorial board of multiple publications, including PLOS One and Investigative Ophthalmology & Visual Sciences. Dr. Foster has been an investigator in a number of large, important clinical trials, funded by the NIH and pharmaceutical companies, in the field of diabetic retinopathy and other ocular diseases.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
ISSUE NO. 4 — Key Considerations for Biosimilar Clinical Pharmacology Studies
Topical and Transdermal – Getting Under Your Skin
The skin is the largest organ of the human body, measuring 22 square feet, on average.
WHAT IT TAKES — Central Nervous System (CNS) Clinical Trials
Biopharmaceutical companies developing new CNS products can face special obstacles.
Selective Quantitation of 1,3-Propanediol in Dog Plasma Using Differential Ion Mobility Spectrometry
ISSUE NO. 3 — Assessing Human Abuse Potential to Limit the Misuse and Abuse of Prescription Drugs
IBS? Don’t Despair – There are Options!
IBS is the name doctors have given to conditions characterized by cramp like abdominal pains, bloating and bouts of diarrhea and/or constipation. According to an article in Nature, it affects hundreds of millions of people — around 11% of the global population has IBS, with a higher prevalence in North America. As a result, there is a significant need for treatments.
As part of Irritable Bowel Syndrome (IBS) awareness month, we wanted to provide you with insight into potential IBS treatments.
Patient Centricity — taking care of our most valuable asset!
“Patient centricity” is the process of designing a service or solution around the patient; more specifically, it is collectively defined as “Putting the patient fi